Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunoh...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-10-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/11795549231203503 |
| _version_ | 1797647706086178816 |
|---|---|
| author | Tri Bui Dang Minh Thuan Nghiem Duc Van Phan Nguyen Thanh Tuan Dinh Le Minh Duc Tong Trung Hoang Nguyen Anh Le Tuan Kien Xuan Nguyen Tien Tran Viet Thang Ba Ta Son Tien Nguyen Hai Anh Vu Ba Van Nguyen Dung Nguyen Thi Ngoc Viet Tran Quoc Thanh Bui Duc |
| author_facet | Tri Bui Dang Minh Thuan Nghiem Duc Van Phan Nguyen Thanh Tuan Dinh Le Minh Duc Tong Trung Hoang Nguyen Anh Le Tuan Kien Xuan Nguyen Tien Tran Viet Thang Ba Ta Son Tien Nguyen Hai Anh Vu Ba Van Nguyen Dung Nguyen Thi Ngoc Viet Tran Quoc Thanh Bui Duc |
| author_sort | Tri Bui Dang Minh |
| collection | DOAJ |
| description | Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunohistochemical markers, and recurrence rate in patients with differentiated thyroid cancer. Method: The study was conducted by a descriptive and longitudinal follow-up method on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam. All patients were identified with the BRAF V600E gene mutation by real-time polymerase chain reaction. Results: The rate of BRAF V600E gene mutation in patients with thyroid cancer was 60.8%. Patients with BRAF V600E gene mutation had a significantly higher rate of positive cyclooxygenase 2 (COX-2) and Ki67 markers than those without the mutation (COX-2: odds ratio [OR] = 2.93; 95% confidence interval [CI] = 1.27-6.74, P = .011; Ki67: OR = 3.41; 95% CI = 1.31-8.88, P = .01). A statistically significant relationship was identified between the rate of BRAF V600E mutation and the rate of positive Hector Battifora mesothelial 1 (HBME-1) (B = −1.040; P = .037) and COX-2 (B = −1.123; P = .023) markers. The recurrence rate in patients with BRAF V600E gene mutation was significantly higher than that in those without the mutation ( P = .007). The mean of the recurrence time of patients with BRAF V600E mutation was significantly lower than that in those without the mutation ( P = .011). Conclusions: A high prevalence of BRAF V600E gene mutation was found in thyroid carcinoma patients. The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation. |
| first_indexed | 2024-03-11T15:21:23Z |
| format | Article |
| id | doaj.art-a926585cff564a918a20a4a53bf05ec6 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-03-11T15:21:23Z |
| publishDate | 2023-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-a926585cff564a918a20a4a53bf05ec62023-10-28T13:03:26ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492023-10-011710.1177/11795549231203503Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid CarcinomaTri Bui Dang Minh0Thuan Nghiem Duc1Van Phan Nguyen Thanh2Tuan Dinh Le3Minh Duc Tong4Trung Hoang Nguyen5Anh Le Tuan6Kien Xuan Nguyen7Tien Tran Viet8Thang Ba Ta9Son Tien Nguyen10Hai Anh Vu11Ba Van Nguyen12Dung Nguyen Thi Ngoc13Viet Tran Quoc14Thanh Bui Duc15Centre for Health Professionals Training, Pham Ngoc Thach University of Medicine, Hochiminh, VietnamDepartment of Otolaryngology, Vietnam Military Hospital 103, Vietnam Military Medical University, Hanoi, VietnamDepartment of Biochemistry, Pham Ngoc Thach University of Medicine, Hochiminh, VietnamDepartment of Rheumatology and Endocrinology, Vietnam Military Hospital 103, Medical Military University, Hanoi, VietnamDepartment of Military Hygiene, Vietnam Military Medical University, Hanoi, VietnamDepartment of Military Hygiene, Vietnam Military Medical University, Hanoi, VietnamDepartment of Military Hygiene, Vietnam Military Medical University, Hanoi, VietnamDepartment of Military Medical Command and Organization, Vietnam Medical Military University, Hanoi, VietnamDepartment of Infectious Diseases, Military Hospital 103, Vietnam Medical Military University, Hanoi, VietnamRespiratory Center, Military Hospital 103, Vietnam Medical Military University, Hanoi, VietnamDepartment of Rheumatology and Endocrinology, Vietnam Military Hospital 103, Medical Military University, Hanoi, VietnamDepartment of Thoracic Surgery, Vietnam Military Hospital 103, Medical Military University, Hanoi, VietnamDepartment of Oncology, Military Hospital 103, Vietnam Military Medical University, Hanoi, VietnamDepartment of Military Science and Training, Military Hospital 175, Hochiminh, VietnamIntensive Care Unit, Military Hospital 175, Hochiminh, VietnamInstitute of Trauma and Orthopedics, Military Hospital 175, Hochiminh, VietnamBackground: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunohistochemical markers, and recurrence rate in patients with differentiated thyroid cancer. Method: The study was conducted by a descriptive and longitudinal follow-up method on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam. All patients were identified with the BRAF V600E gene mutation by real-time polymerase chain reaction. Results: The rate of BRAF V600E gene mutation in patients with thyroid cancer was 60.8%. Patients with BRAF V600E gene mutation had a significantly higher rate of positive cyclooxygenase 2 (COX-2) and Ki67 markers than those without the mutation (COX-2: odds ratio [OR] = 2.93; 95% confidence interval [CI] = 1.27-6.74, P = .011; Ki67: OR = 3.41; 95% CI = 1.31-8.88, P = .01). A statistically significant relationship was identified between the rate of BRAF V600E mutation and the rate of positive Hector Battifora mesothelial 1 (HBME-1) (B = −1.040; P = .037) and COX-2 (B = −1.123; P = .023) markers. The recurrence rate in patients with BRAF V600E gene mutation was significantly higher than that in those without the mutation ( P = .007). The mean of the recurrence time of patients with BRAF V600E mutation was significantly lower than that in those without the mutation ( P = .011). Conclusions: A high prevalence of BRAF V600E gene mutation was found in thyroid carcinoma patients. The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation.https://doi.org/10.1177/11795549231203503 |
| spellingShingle | Tri Bui Dang Minh Thuan Nghiem Duc Van Phan Nguyen Thanh Tuan Dinh Le Minh Duc Tong Trung Hoang Nguyen Anh Le Tuan Kien Xuan Nguyen Tien Tran Viet Thang Ba Ta Son Tien Nguyen Hai Anh Vu Ba Van Nguyen Dung Nguyen Thi Ngoc Viet Tran Quoc Thanh Bui Duc Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma Clinical Medicine Insights: Oncology |
| title | Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma |
| title_full | Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma |
| title_fullStr | Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma |
| title_full_unstemmed | Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma |
| title_short | Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma |
| title_sort | relationships of braf v600e gene mutation with some immunohistochemical markers and recurrence rate in patients with thyroid carcinoma |
| url | https://doi.org/10.1177/11795549231203503 |
| work_keys_str_mv | AT tribuidangminh relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT thuannghiemduc relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT vanphannguyenthanh relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT tuandinhle relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT minhductong relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT trunghoangnguyen relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT anhletuan relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT kienxuannguyen relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT tientranviet relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT thangbata relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT sontiennguyen relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT haianhvu relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT bavannguyen relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT dungnguyenthingoc relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT viettranquoc relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma AT thanhbuiduc relationshipsofbrafv600egenemutationwithsomeimmunohistochemicalmarkersandrecurrencerateinpatientswiththyroidcarcinoma |